20-185 - A Trial to Evaluate the Efficacy and Safety of RSVpreF in Infants Born to Women Vaccinated During Pregnancy.Status: open
This project is designed to evaluate the efficacy and safety of maternal immunization with RSVpreF against medically attended lower respiratory track illness in infants. Pregnant women will be given a stabilized RSV prefusion F subunit vaccine or placebo during late 2nd trimester or early 3rd trimester of pregnancy. There will be infant follow-up for 24 months.
Prevent respiratory syncytial virus (RSV) disease by immunizing pregnant women
This study evaluates the use of Digoxin immune fab in addition to expectant management in the treatment of severe preeclampsia as compared to placebo.
SponsorsThis trial is sponsored by Pfizer.
Providers Associated With This Trial
- Tracy Y. Roth, M.D.Obstetrician/GynecologistResidency Program Director for Obstetrics and Gynecology; Assistant Professor of Obstetrics and Gynecology; Focused Practice Designation in Pediatric and Adolescent Gynecology
- Benjamin Estrada, M.D.Pediatric Infectious DiseaseAssistant Dean for Educational Strategies and Faculty Development; Professor and Vice Chair of Pediatrics
- Nicolette P. Holliday, M.D., F.A.C.O.G.Obstetrician/GynecologistAssociate Professor of Obstetrics and Gynecology/Focused Practice Designation in Pediatric and Adolescent Gynecology